EMA Panel Backs Zanamivir IV for Complicated, Severe Influenza EMA Panel Backs Zanamivir IV for Complicated, Severe Influenza

The EMA ' s Committee for Medicinal Products for Human Use recommended marketing authorization under exceptional circumstances for zanamivir for complicated and potentially life-threatening influenza.International Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Infectious Diseases News Source Type: news